Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Phase II-III Multi-Centre Study to Evaluate the Effect of Adjuvant Pazopanib (GW786034) Versus Placebo on Post-Surgical Disease-Free Survival in Patients With Stage I Non Small Cell Lung Cancer and Tumor Size Equal or Inferior to 7 cm

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II-III Multi-Centre Study to Evaluate the Effect of Adjuvant Pazopanib (GW786034) Versus Placebo on Post-Surgical Disease-Free Survival in Patients With Stage I Non Small Cell Lung Cancer and Tumor Size Equal or Inferior to 7 cm

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 01 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2017 According to results published in the Annals of Oncology, a protocol has amended to reduce dose of the pazopanib from 800 mg/day to 400 mg/day due to insufficient compliance.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top